Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
4
×
boston blog main
life sciences
national blog main
san francisco blog main
4
×
san francisco top stories
4
×
boston top stories
national top stories
deals
new york blog main
new york top stories
san francisco
startups
abeona therapeutics
affordable care act
agios pharmaceuticals
alirocuma
alphabet
alzheimer's
ameet nathwani
arches
azacitidine
beta-thalassemia
boston
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
broad institute of harvard and mit
brook byers
cancer diagnostics
charles chu
crispr
crispr cas14
dacogen
david schenkein
debate
decheng capital
decitabine
detroit blog main
detroit top stories
What
based
4
×
bio
developing
aims
american
announced
approach
area
available
bay
best
big
biopsy
biosciences
biotech
blood
buildout
called
cancer
cas
cheaper
close
company
continue
crash
crispr
debate
debuts
develop
diagnostics
drugs
epigenetic
epigenetics
expects
faster
field
firm
flagship’s
genomic
healthcare
Language
unset
Current search:
based
×
biotech
×
" san francisco blog main "
×
" san francisco top stories "
×
@xconomy.com
4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
4 years ago
Liquid Biopsy Firm Lucence Plans Bay Area Buildout With $20M in Tow
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
5 years ago
Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More